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among hospitalized patients is substantial. Further research is
needed to assess the value of large hospital discharge databases
for documenting and distinguishing the costs of speciﬁc bacter-
ial pathogens.
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OBJECTIVES: To project the potential impact of pandemic
inﬂuenza mitigation strategies on health outcome, cost, and cost-
effectiveness from a societal perspective. METHODS: We use a
stochastic agent-based model to simulate pandemic inﬂuenza in
the community. We compare 16 strategies to no intervention,
focusing on targeted antiviral prophylaxis (TAP) with
oseltamivir (treatment of identiﬁed index cases and prophylaxis
of exposed people) alone and in combination with school
closure. We also consider pre-vaccination of the population. We
use the human capital approach to estimate productivity loss.
Outcomes include number of cases, deaths, QALYs, direct and
indirect costs, and incremental cost-effectiveness ratios (ICERs)
expressed as costs per QALY gained. RESULTS: In the absence
of intervention, we predict a 50% attack rate with an economic
impact of $187 per capita. TAP + school closure and pre-vacci-
nation + school closure (preventing 94–96% of cases at $2730
per capita)) are comparable in terms of QALY gain and total
costs. The ICER compared to TAP alone (the most effective
single strategy) is about $50,500/QALY for either strategy. The
most effective single strategy is TAP alone (prophylaxis of 60%
of close contacts of index cases) which effectively prevents 54%
of cases at a cost of $120 per capita. If vaccine is available and
administered before the onset of the pandemic, then pre-vacci-
nating 70% of the population with a partially effective vaccine
prevents 48% of cases and is the least costly alternative ($99 per
capita), dominating all but one TAP only strategies, treatment
and school closure. Sensitivity analysis on key variables does not
change the ranking of strategies but shows that mortality has the
greatest impact on QALYs and hence ICERs. CONCLUSION:
Targeted antiviral prophylaxis is an effective and cost-saving
measure for mitigating pandemic inﬂuenza. Adding school
closure provides greater beneﬁt and is likely to be an attractive
strategy if mortality is high.
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OBJECTIVES: To assess the impact of severity of obesity on
medical comorbidities, perceived health status and medical costs
in the US. METHODS: This study analyzed the 2004 Medical
Expenditure Panel Survey (MEPS). Based on the Body Mass
Index (BMI), weight groups were deﬁned as Underweight (UW,
BMI < 18.5), Normal Weight (NW, BMI 18.5–24.9), Overweight
(OW, BMI 25–29.9), Obese I (BMI 30–34.9), Obese II (BMI
35–39.9), and Obese III (BMI >= 40). Multiple logistic regres-
sions were modeled to estimate the impact of severity of obesity
on medical comorbidities and perceived health status. Two part
models (TPMs) were employed to estimate the cost functions
controlling for socio-demographic characteristics and physical
health conditions. All estimates are weighted to be nationally
representative and the costs are adjusted for the Smearing effect.
RESULTS: In the nationally representative sample (mean age
45.5 years; 51.4% female), 2.1% were UW, 37.0% NW, 35.1%
OW, 16.4% obese I, 6.1% obese II and 3.4% obese III. Com-
pared to NW, obese I, II and III were more likely to have dia-
betes (odds ratio (OR) = 3.5, 5.7, and 10.8, p < 0.001), asthma
(OR = 1.4, 2.1, and 2.6, p < 0.001), and joint pain (OR = 1.7,
2.2 and 2.9, p < 0.001), and reported signiﬁcantly poorer per-
ceived health status (OR = 0.6, 0.4 and 0.3, p < 0.001), respec-
tively. The TPMs results showed that compared to NW patients,
obese II and III were more likely to incur higher costs (OR = 1.3,
and 1.4, p < 0.05), and patients from obese I, II and II also had
signiﬁcantly higher costs compared to NW patients ($4643,
$5000, $4811 vs. $3999, p < 0.001). CONCLUSION: Obesity
is a major public health concern and has a large economic impact
to the US population. The severity of obesity is signiﬁcantly asso-
ciated with increased medical comorbidities, decreased health
status and high medical costs.
OB2
THE COST OF THE METABOLIC SYNDROME IN THE ELDERLY:
FINDINGS FROM THE CARDIOVASCULAR HEALTH STUDY
Curtis LH1, Hammill BG1, Bethel MA1,Anstrom KJ2, Gottdiener JS3,
Schulman KA2
1Duke University, Durham, NC, USA, 2Duke Clinical Research
Institute, Durham, NC, USA, 3University of Maryland Hospital,
Baltimore, MD, USA
OBJECTIVES: The cardiovascular consequences of the meta-
bolic syndrome and its component risk factors (i.e., abdominal
obesity, low HDL cholesterol or elevated triglyercides, hyper-
tension, elevated blood glucose) have been documented in the
elderly. To date, little is known about how the metabolic syn-
drome and its components translate into long-term medical
costs. METHODS: We used clinical data and matching, longi-
tudinal Medicare claims from 3789 individuals aged 65 years
and older in the Cardiovascular Health Study followed up to 10
years. The metabolic syndrome was deﬁned according to the
National Cholesterol Education Program’s Third Adult Treat-
ment Panel Report (NCEP-ATP III) criteria. W calculated costs
by summing Medicare payment amounts for each participant,
and discounted costs at 3% annually. Log-linear regression
models were used to assess the independent contributions of the
metabolic syndrome and its component risk factors to 10-year
medical costs among. RESULTS: As deﬁned by the NCEP ATP
III criteria, the metabolic syndrome was present in 47% of the
sample. Total per patient costs to Medicare were 20% higher
among those with the metabolic syndrome ($40,827 vs. $32,962,
p < 0.001). Controlling for age, gender, race and other covari-
ates, abdominal obesity, low HDL cholesterol, and elevated
blood pressure were associated with 15% (95% conﬁdence inter-
val [CI] 4.3%–26.7%), 16% (CI: 1.1%–31.8%), and 20% (CI
10.1%–31.7%) higher total costs, respectively. When added to
the model, the metabolic syndrome composite variable did not
contribute signiﬁcantly (p = 0.32). CONCLUSION: Abdominal
obesity, low HDL cholesterol, and hypertension, but not the
metabolic syndrome, are important predictors of long-term costs
in the Medicare population. The combined effects of abdominal
obesity, low HDL cholesterol, and elevated blood pressure are
associated with 50% higher Medicare costs.
